What is Timorite DPS.?
Timorite DPS. is used alone or together with other medicines (such as hydrochlorothiazide) to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Timorite DPS. is also used after an acute heart attack to decrease its severity and prevent another heart attack. It may also be used to help prevent migraine headaches.
Timorite DPS. is a beta-blocker. It works by affecting the response to nerve impulses in certain parts of the body, like the heart. As a result, the heart beats slower and decreases the blood pressure. When the blood pressure is lowered, the amount of blood and oxygen is increased to the heart.
Timorite DPS. is available only with your doctor's prescription.
Timorite DPS. indications
Hypertension
Timorite DPS. tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
Myocardial Infarction
Timorite DPS. is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.
Migraine
Timorite DPS. is indicated for the prophylaxis of migraine headache.
How should I use Timorite DPS.?
Use Timorite DPS. as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Timorite DPS. by mouth with or without food.
- If you miss a dose of Timorite DPS., take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Timorite DPS..
Uses of Timorite DPS. in details
Use: Labeled Indications
Hypertension: Management of hypertension. Note: Beta-blockers are not recommended as first-line therapy (ACC/AHA [Whelton 2017]).
Migraine prophylaxis: Prophylaxis of migraine
Myocardial infarction (secondary prevention): To reduce mortality following MI
Off Label Uses
Atrial fibrillation (rate-control)
Data from a randomized, placebo-controlled trial in patients with atrial fibrillation (AF) associated with a rapid ventricular response while receiving digoxin supports the use of oral Timorite DPS. in patients with chronic AF.
Based on the 2014 AHA/ACC/HRS guideline for the management of patients with AF, the use of beta-blockers for ventricular rate control in patients with paroxysmal, persistent, or permanent AF is effective and recommended for this condition.
Timorite DPS. description
A beta-adrenergic antagonist similar in action to propranolol. The levo-isomer is the more active. Timorite DPS. has been proposed as an antihypertensive, antiarrhythmic, antiangina, and antiglaucoma agent. It is also used in the treatment of migraine disorders and tremor.
Timorite DPS. dosage
Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once. Other topically applied ophthalmic medications should be administered at least 10 minutes before Timorite DPS. Ophthalmic Gel Forming Solution.
Timorite DPS. Ophthalmic Gel Forming Solution is available in concentrations of 0.25% and 0.5%. The dose is one drop of Timorite DPS. Ophthalmic Gel Forming Solution (either 0.25% or 0.5%) in the affected eye(s) once a day.
Because in some patients the pressure-lowering response to Timorite DPS. Ophthalmic Gel Forming Solution may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Timorite DPS. Ophthalmic Gel Forming Solution.
Dosages higher than one drop of 0.5% Timorite DPS. Ophthalmic Gel Forming Solution once a day have not been studied. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy can be considered. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.
When patients have been switched from therapy with Timorite DPS. ophthalmic solution administered twice daily to Timorite DPS. Ophthalmic Gel Forming Solution administered once daily, the ocular hypotensive effect has remained consistent.
Timorite DPS. interactions
See also:
What other drugs will affect Timorite DPS.?
Although TIMOPTIC (Timorite DPS. ophthalmic solution) used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with TIMOPTIC (Timorite DPS. ophthalmic solution) and epinephrine has been reported occasionally.
Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and Preservative-free Timorite DPS. should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.
Calcium antagonists: Caution should be used in the coadministration of beta-adrenergic blocking agents, such as Preservative-free Timorite DPS., and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, coadministration should be avoided.
Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
Digitalis and calcium antagonists: The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
CYP2D6 inhibitors: Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and Timorite DPS..
Clonidine:
Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. There have been no reports of exacerbation of rebound hypertension with ophthalmic Timorite DPS.. Injectable epinephrine:
Timorite DPS. side effects
See also:
What are the possible side effects of Timorite DPS.?
Timorite DPS. tablets are usually well tolerated in properly selected patients. Most adverse effects have been mild and transient.
In a multi-center (12 week) clinical trial comparing Timorite DPS. and placebo in hypertensive patients, the following adverse reactions were reported spontaneously and considered to be causally related to Timorite DPS.:
| Timorite DPS. (n=176) % | Placebo (n=168) % | |
|---|---|---|
| BODY AS A WHOLE | ||
| fatigue/tiredness | 3.4 | 0.6 |
| headache | 1.7 | 1.8 |
| chest pain | 0.6 | 0 |
| asthenia | 0.6 | 0 |
| CARDIOVASCULAR | ||
| bradycardia | 9.1 | 0 |
| arrhythmia | 1.1 | 0.6 |
| syncope | 0.6 | 0 |
| edema | 0.6 | 1.2 |
| DIGESTIVE | ||
| dyspepsia | 0.6 | 0.6 |
| nausea | 0.6 | 0 |
| SKIN | ||
| pruritus | 1.1 | 0 |
| NERVOUS SYSTEM | ||
| dizziness | 2.3 | 1.2 |
| vertigo | 0.6 | 0 |
| paresthesia | 0.6 | 0 |
| PSYCHIATRIC | ||
| decreased libido | 0.6 | 0 |
| RESPIRATORY | ||
| dyspnea | 1.7 | 0.6 |
| bronchial spasm | 0.6 | 0 |
| rales | 0.6 | 0 |
| SPECIAL SENSES | ||
| eye irritation | 1.1 | 0.6 |
| tinnitus | 0.6 | 0 |
These data are representative of the incidence of adverse effects that may be observed in properly selected patients treated with Timorite DPS., i.e., excluding patients with bronchospastic disease, congestive heart failure or other contraindications to beta-blocker therapy.
In patients with migraine the incidence of bradycardia was 5 percent.
In a coronary artery disease population studied in the Norwegian multi-center trial, the frequency of the principal adverse reactions and the frequency with which these resulted in discontinuation of therapy in the Timorite DPS. and placebo groups were:
| Adverse Reaction* | Withdrawal† | |||
|---|---|---|---|---|
| Timorite DPS. (n=945) % | Placebo (n=939) % | Timorite DPS. (n=945) % | Placebo (n=939) % | |
| ||||
| Asthenia or Fatigue | 5 | 1 | <1 | <1 |
| Heart Rate < 40 beats/minute | 5 | <1 | 4 | <1 |
| Cardiac Failure-Nonfatal | 8 | 7 | 3 | 2 |
| Hypotension | 3 | 2 | 3 | 1 |
| Pulmonary Edema-Nonfatal | 2 | <1 | <1 | <1 |
| Claudication | 3 | 3 | 1 | <1 |
| AV Block 2nd or 3rd Degree | <1 | <1 | <1 | <1 |
| Sinoatrial Block | <1 | <1 | <1 | <1 |
| Cold Hands and Feet | 8 | <1 | <1 | 0 |
| Nausea or Digestive Disorders | 8 | 6 | 1 | <1 |
| Dizziness | 6 | 4 | 1 | 0 |
| Bronchial Obstruction | 2 | <1 | 1 | <1 |
The following additional adverse effects have been reported in clinical experience with the drug: Body as a Whole: anaphylaxis, extremity pain, decreased exercise tolerance, weight loss, fever; Cardiovascular: cardiac arrest, cardiac failure, cerebral vascular accident, worsening of angina pectoris, worsening of arterial insufficiency, Raynaud's phenomenon, palpitations, vasodilatation; Digestive: gastrointestinal pain, hepatomegaly, vomiting, diarrhea, dyspepsia; Hematologic: nonthrombocytopenic purpura; Endocrine: hyperglycemia, hypoglycemia; Skin: rash, skin irritation, increased pigmentation, sweating, alopecia; Musculoskeletal: arthralgia; Nervous System: local weakness, increase in signs and symptoms of myasthenia gravis; Psychiatric: depression, nightmares, somnolence, insomnia, nervousness, diminished concentration, hallucinations; Respiratory: cough; Special Senses: visual disturbances, diplopia, ptosis, dry eyes; Urogenital: impotence, urination difficulties.
There have been reports of retroperitoneal fibrosis in patients receiving Timorite DPS. and in patients receiving other beta-adrenergic blocking agents. A causal relationship between this condition and therapy with beta-adrenergic blocking agents has not been established.
Potential Adverse Effects
In addition, a variety of adverse effects not observed in clinical trials with Timorite DPS., but reported with other beta-adrenergic blocking agents, should be considered potential adverse effects of Timorite DPS.. Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics; Cardiovascular: Intensification of AV block; Digestive: Mesenteric arterial thrombosis, ischemic colitis; Hematologic: Agranulocytosis, thrombocytopenic purpura; Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; Miscellaneous: Peyronie's disease.
There have been reports of a syndrome comprising psoriasiform skin rash, conjunctivitis sicca, otitis, and sclerosing serositis attributed to the beta-adrenergic receptor blocking agent, practolol. This syndrome has not been reported with Timorite DPS..
Clinical Laboratory Test Findings
Clinically important changes in standard laboratory parameters were rarely associated with the administration of Timorite DPS.. Slight increases in blood urea nitrogen, serum potassium, uric acid, and triglycerides, and slight decreases in hemoglobin, hematocrit and HDL cholesterol occurred, but were not progressive or associated with clinical manifestations. Increases in liver function tests have been reported.
Timorite DPS. contraindications
See also:
What is the most important information I should know about Timorite DPS.?
Hypersensitivity to Timorite DPS. or any component of the formulation; sinus bradycardia; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure; bronchospastic disease
Documentation of allergenic cross-reactivity for beta-blockers is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Canadian labeling: Additional contraindications (not in US labeling): Right ventricular failure secondary to pulmonary hypertension; significant cardiomegaly; allergic rhinitis; severe chronic obstructive pulmonary disease; anesthesia with agents that produce myocardial depression (eg, ether hypersensitivity to Timorite DPS.)
Active ingredient matches for Timorite DPS.:
| Unit description / dosage (Manufacturer) | Price, USD |
| TIMORITE DPS. Eye Drops / / 5ml units (Klar Sehen) | $ 0.51 |
List of Timorite DPS. substitutes (brand and generic names): | |
| Timolol (Argentina, Australia, Austria, Bahrain, Belgium, Bosnia & Herzegowina, Brazil, Bulgaria, Canada, Chile, Costa Rica, Croatia (Hrvatska), Czech Republic, Denmark, El Salvador, Estonia, Finland, France, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Malaysia, Malta, Mexico, Netherlands, New Zealand, Nicaragua, Norway, Panama, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, United Kingdom, United States, Venezuela) | |
| Timolol / Medicine 0.5 % x 5 mL (Calibre Pharmaceutical Pvt. Ltd.) | |
| Timolol / Wu Fu 0.25 % x 5 mL (Calibre Pharmaceutical Pvt. Ltd.) | |
| Timolol / Wu Fu 0.5 % x 5 mL (Calibre Pharmaceutical Pvt. Ltd.) | |
| Timolol Eye 5 ml Drop (Calibre Pharmaceutical Pvt. Ltd.) | $ 0.07 |
| Timolol 0,5% Alcon (Vietnam) | |
| Timolol 0, 5% Alcon 0.5 % x 1 Bottle 5 mL | |
| Timolol Chauvin 0.5% (Vietnam) | |
| Timolol Chauvin 0.5% 0.5 % x 1 Bottle 5 mL | |
| Timolol GFS | |
| 2.5 milliliter in 1 bottle, plastic | |
| 5 milliliter in 1 bottle, plastic | |
| Timolol Gfs solution, gel forming, extended release 2.5 mg/mL (Sandoz Inc (US)) | |
| Timolol Gfs solution, gel forming, extended release 5 mg/mL (Sandoz Inc (US)) | |
| Timolol Maleate | |
| 100 tablet in 1 bottle, plastic | |
| Timolol Maleate solution 6.8 mg/mL (Physicians Total Care, Inc. (US)) | |
| Timolol Maleate solution 2.5 mg/mL (Aton Pharma, Inc. (US)) | |
| Timolol Maleate solution 5 mg/mL (Aton Pharma, Inc. (US)) | |
| Timolol Maleate solution/ drops 5 mg/mL (Hi Tech Pharmacal Co., Inc. (US)) | |
| Timolol Maleate tablet 5 mg/1 (Mylan Pharmaceuticals Inc. (US)) | |
| Timolol Maleate solution/ drops 2.5 mg/mL (Fdc Limited (US)) | |
| Timolol Maleate tablet 10 mg/1 (Mylan Pharmaceuticals Inc. (US)) | |
| Timolol Maleate tablet 20 mg/1 (Mylan Pharmaceuticals Inc. (US)) | |
| Timolol Pos | |
| Timolyre 0.5% | |
| Timoptic in Ocudose | |
| Solution; Ophthalmic; Timolol Maleate 0.25% | |
| Solution; Ophthalmic; Timolol Maleate 0.5% | |
| Timoptol 添慕寧 (Hongkong) | |
| Timoptol eye drops 0.5 % 5 mL x 1's (Santen) | |
| Timorite | |
| Timorite Eye 5 ml Drop (Klar Sehen Pvt. Limited) | $ 0.11 |
| TIMORITE 0.5% EYE DROPS 1 packet / 5 ML eye drop each (Klar Sehen Pvt. Limited) | $ 0.66 |
| Timorite 0.5% Eye Drop (Klar Sehen Pvt. Limited) | $ 0.73 |
| TIMORIV (India) | |
| 0.5 % w/v x 5ml (East African (I) Remedies (P) Ltd.) | $ 0.48 |
| Timoriv 0.5 % w/v EYE DPS / 5ml (East African (I) Remedies (P) Ltd.) | $ 0.48 |
| Timoriv Eye 5 ml Drop (East African (I) Remedies (P) Ltd.) | $ 0.48 |
| TIMORIV eye drops 0.5 % w/v x 5ml (East African (I) Remedies (P) Ltd.) | $ 0.48 |
| Timoriv 0.5 % w/v EYE DPS / 5ml (East African (I) Remedies (P) Ltd.) | $ 0.48 |
| Timostal (Philippines) | |
| Timostal ophth soln 0.5% 10 mL x 1's (Stallion Labs) | |
| Timozen | |
| Timozen Eye 5 ml Drop (Kaizen Drugs (P) Ltd.) | $ 0.42 |
| TIMOZEN 0.5%W/V EAR DROPS 1 packet / 5 ML ear drop each (Kaizen Drugs (P) Ltd.) | $ 0.60 |
| Timozen 0.5% w/v Eye Drop (Kaizen Drugs (P) Ltd.) | $ 0.60 |
| TIMTAL (India) | |
| 0.5 % x 5ml (Talson Pharmaceuticals) | $ 0.46 |
| Timtal 0.5 % EYE DPS / 5ml (Talson Pharmaceuticals) | $ 0.46 |
| Timtal Eye 5 ml Drop (Talson Pharmaceuticals) | $ 0.46 |
| TIMTAL eye drops 0.5 % x 5ml (Talson Pharmaceuticals) | $ 0.46 |
| Timtal 0.5 % EYE DPS / 5ml (Talson Pharmaceuticals) | $ 0.46 |
See 230 substitutes for Timorite DPS. | |
References
- DailyMed. "TIMOLOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "timolol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "timolol". http://www.drugbank.ca/drugs/DB00373 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Timorite DPS. are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Timorite DPS.. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
